| Filed On | Filing |
|---|---|
| 04 Nov 2026 |
8-K: Results of Operations and Financial Condition
HAYWARD, Calif. – (BUSINESS WIRE) – Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of cancer and immune d... |
| 23 Oct 2026 |
8-K: Other Events
Arcus Biosciences, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwrite... |
| 21 Oct 2026 |
8-K: Results of Operations and Financial Condition
Based upon preliminary estimates and information available to Arcus Biosciences, Inc. (the “Company”) as of October 21, 2026, the Company estimates that it had approximately $694.0 million in cash, cash equivalents and marketable securit... |
| 20 Oct 2026 |
8-K: Other Events
On October 20, 2026, Arcus Biosciences, Inc. presented new data from the ARC-20 platform study evaluating casdatifan, alone or in combination, as a first-, second- and late-line treatment for clear cell renal cell carcinoma (“ccRCC”). Th... |
| 05 Aug 2026 |
8-K: Results of Operations and Financial Condition
HAYWARD, Calif. – (BUSINESS WIRE) – Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory ... |
| 12 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 11, 2026, Arcus Biosciences, Inc. (the "Company") held its annual meeting of stockholders. The results of the stockholder votes on each proposal brought before the Annual Meeting is as follows: |
| 05 May 2026 |
8-K: Results of Operations and Financial Condition
HAYWARD, Calif. – (BUSINESS WIRE) – Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory ... |
| 20 Apr 2026 |
8-K: Other Events
On April 20, 2026, Arcus Biosciences, Inc. (the “Company”) announced the discontinuation of the Phase 3 STAR-121 study, which is being conducted in collaboration with Gilead Sciences, Inc. (“Gilead”), due to futility. STAR-121 evaluated ... |
| 23 Mar 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On March 17, 2026, Jennifer Jarrett notified Arcus Biosciences, Inc. (the “Company”) of her decision to resign from her position as Chief Operating Officer, effective as of March 30, 2026. Ms. Jarrett’s resignation is not the result of a... |
| 25 Feb 2026 |
8-K: Results of Operations and Financial Condition
HAYWARD, Calif. – (BUSINESS WIRE) – Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer and inflammator... |
| 18 Dec 2025 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation
On December 18, 2025 (the “Closing Date”), Arcus Biosciences, Inc. (the “Company”) entered into a First Amendment to the Loan and Security Agreement (the “First Amendment”) with the several banks and other financial institutions or entit... |
| 12 Dec 2025 |
8-K: Other Events
On December 12, 2025, Arcus Biosciences, Inc. (the “Company”) announced the discontinuation of the Phase 3 STAR-221 study due to futility. STAR-221 evaluated the anti-TIGIT antibody domvanalimab plus anti-PD-1 antibody zimberelimab and c... |
| 03 Nov 2025 |
8-K: Other Events
Arcus Biosciences, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwrite... |
| 28 Oct 2025 |
8-K: Results of Operations and Financial Condition
HAYWARD, Calif. – (BUSINESS WIRE) – Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, inflammatory a... |
| 14 Oct 2025 |
8-K: Other Events
On October 12, 2025, Arcus Biosciences, Inc. (the “Company”) announced the first overall survival results from Arm A1 of the Phase 2 EDGE-Gastric study in patients with locally advanced unresectable or metastatic gastric, gastroesophagea... |
| 06 Oct 2025 |
8-K: Other Events
On October 6, 2025, Arcus Biosciences, Inc. (the “Company”) presented updated data from the monotherapy cohorts of ARC-20, a Phase 1/1b study evaluating different doses and combinations with casdatifan, and shared new research programs i... |
| 06 Aug 2025 |
8-K: Results of Operations and Financial Condition
HAYWARD, Calif. – (BUSINESS WIRE) – Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today reported... |
| 12 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders; Other Events
Annual cash retainers each paid quarterly, in arrears, as follows: |
| 02 Jun 2025 |
8-K: Regulation FD Disclosure; Other Events
On June 1, 2025, Arcus Biosciences, Inc. (the “Company”) presented updated information about its portfolio and development programs. An updated corporate presentation has been posted to the Investors & Media section of the Company’s webs... |
| 06 May 2025 |
8-K: Results of Operations and Financial Condition
HAYWARD, Calif. – (BUSINESS WIRE) – Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today reported... |
Loading...